Organovo Holdings, Inc. — Form 10-Q Summary
Filing identity: The filing is for Organovo Holdings, Inc. (Nasdaq: ONVO), not “Vivosim Labs, INC.” as stated in the request metadata. The quarterly period ended December 31, 2021, corresponding to Organovo’s fiscal 2022 third quarter. Financial statements are unaudited.
Business context
Organovo is an early-stage biotechnology company developing 3D human tissue and disease models for drug discovery. Its initial focus is inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; the company intends to identify and validate drug targets and ultimately develop drug candidates. The filing reports no revenue line in the presented statements.
Financial results and position
| Metric | Three months ended Dec. 31, 2021 | Nine months ended Dec. 31, 2021 |
|---|---|---|
| Revenue | Not reported in the statements | Not reported in the statements |
| Research and development expense | $0.926 million | $2.185 million |
| Selling, general and administrative expense | $2.574 million | $7.381 million |
| Total operating expenses | $3.500 million | $9.566 million |
| Net loss | $3.500 million | $9.537 million |
| Basic and diluted loss per share | $0.40 | $1.10 |
For the nine months, net cash used in operating activities was $6.912 million; investing activities used $0.356 million; financing activities provided $0.205 million. Cash, cash equivalents and restricted cash declined $7.063 million to $30.412 million, including $30.269 million of cash and cash equivalents and $0.143 million of restricted cash. The company reported working capital of $29.2 million and an accumulated deficit of $305.8 million at December 31, 2021.
Total liabilities were $3.802 million, primarily operating lease liabilities; no borrowings or other financial debt are reported. The permanent facility lease commenced in December 2021, with $2.271 million of lease liabilities recognized. Gross margin is not meaningful based on the filing’s presented results.
Changes versus the comparable period
- Third-quarter R&D expense rose 130% year over year, reflecting increased staffing and research activity after operations resumed following the September 2020 change of control. Average R&D headcount rose from four to eleven.
- Third-quarter SG&A increased 23% year over year. The filing attributes the increase to personnel and corporate costs, including legal expenses related to patent proceedings and enforcement litigation.
- For the nine-month comparison, R&D expense increased 408%, while SG&A fell 47%. The prior-year period included strategic-alternatives activity, executive departures and accelerated stock compensation after the change of control.
- Nine-month operating cash use improved to $6.912 million from $11.209 million, which management attributed primarily to the change in business operations. Cash and cash equivalents fell from $37.364 million at March 31, 2021 to $30.269 million at December 31, 2021.
Outlook, risks and unusual items
- Management forecasts fiscal 2022 total operating expense of $12 million to $14 million and believes available cash will fund operations for at least 12 months. It also says additional capital will be needed to implement the business plan; future financing availability and terms are uncertain.
- Management expects R&D headcount and activity to increase, with associated expense growth. The company does not expect meaningful revenue in the foreseeable future and warns it may never achieve profitability.
- The company sold 27,545 shares through its ATM program for approximately $0.3 million net proceeds during the nine months. At period-end, approximately $28.3 million remained available under the ATM program and $128.3 million under the shelf registration statement.
- Patent disputes with Cellink included IPR petitions and patent litigation. The PTAB denied institution of two IPR proceedings in December 2021; other petitions remained pending at the reporting date. On January 24, 2022, Organovo and BICO Group (Cellink’s parent) signed a binding settlement term sheet contemplating an IP license and payments to Organovo. Final terms and amounts are not provided here. No loss contingency accrual was recorded.
- COVID-19, reliable access to human cells, the unproven drug-discovery strategy, financing needs and dilution, competition, and intellectual-property challenges are material risks. Management said operations had not been negatively affected by the pandemic at the time of filing.
- Disclosure controls were assessed as effective, and the company reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing entity and ticker: this is Organovo Holdings, Inc. (ONVO), notwithstanding the request metadata naming Vivosim Labs, INC.
- Review subsequent disclosures for the final BICO settlement and license terms, including payment amounts, timing and scope.
- Assess cash burn against the stated 12-month runway and the planned $12 million to $14 million fiscal 2022 operating expense range.
- Track R&D progress toward validated targets and drug candidates, since the company reports no meaningful revenue and describes its strategy as unproven.
- Monitor remaining patent proceedings, potential legal costs, future financing and dilution, and access to human-cell supplies.